Characterizing the clinical adoption of medical AI devices through US insurance claims
There are now over 500 medical artificial intelligence (AI) devices that are approved by the
US Food and Drug Administration. However, little is known about where and how often …
US Food and Drug Administration. However, little is known about where and how often …
HMGB1 promotes the proliferation and metastasis of lung cancer by activating the Wnt/β-catenin pathway
X Wang, S Zhang, M Shi, X Xu - Technology in Cancer …, 2020 - journals.sagepub.com
The aim of this study was to investigate the role of high mobility group protein-1 (HMGB1) in
the proliferation and migration of lung cancer cells. CCK-8 assays and colony formation …
the proliferation and migration of lung cancer cells. CCK-8 assays and colony formation …
Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States
X Zhang, DC Beachler, E Masters, F Liu… - Journal of Managed …, 2022 - jmcp.org
BACKGROUND: The treatment landscape for advanced nonsmall cell lung cancer (NSCLC)
has evolved from 2015 onward, since the introduction of immune checkpoint inhibitors (ICIs) …
has evolved from 2015 onward, since the introduction of immune checkpoint inhibitors (ICIs) …
Economic analyses of immune-checkpoint inhibitors to treat lung cancer
A Vergnenegre, C Chouaid - Expert review of pharmacoeconomics …, 2021 - Taylor & Francis
Introduction: Total lung-cancer–management costs are increasing dramatically. The
widespread use of immune-checkpoint inhibitors (ICIs) explains this rise in large part and …
widespread use of immune-checkpoint inhibitors (ICIs) explains this rise in large part and …
Comparative effectiveness of lobectomy, segmentectomy, and wedge resection for pathological stage I non-small cell lung cancer in elderly patients: a population …
X Zhang, G Lin, J Li - Frontiers in Surgery, 2021 - frontiersin.org
Introduction: This study was designed to assess the long-term survival of lobectomy,
segmentectomy, and wedge resection for pathological stage I non-small cell lung cancer …
segmentectomy, and wedge resection for pathological stage I non-small cell lung cancer …
Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung …
IM Abbass, DM Sheinson, A Shah, A Gondos… - Journal of Managed …, 2024 - jmcp.org
BACKGROUND: Clinical practice guidelines recommend broad-panel genomic profiling to
identify actionable genomic alterations for patients with advanced non–small cell lung …
identify actionable genomic alterations for patients with advanced non–small cell lung …
[HTML][HTML] Toward better data dashboards for US drug value assessments
PJ Neumann - Value in Health, 2021 - Elsevier
Objectives To explore the use of data dashboards to convey information about a drug's
value, and reduce the need to collapse dimensions of value to a single measure. Methods …
value, and reduce the need to collapse dimensions of value to a single measure. Methods …
[Retracted] Clinical Efficacy of Single‐Port Thoracoscopic Lobectomy versus Three‐Port Thoracoscopic Lobectomy for Lung Cancer
Y Xu, Y Zhou, F Lv, Y Liu, X Ji - Journal of oncology, 2022 - Wiley Online Library
Objective. To evaluate the clinical efficacy of single‐port thoracoscopic lobectomy versus
three‐port thoracoscopic lobectomy for lung cancer. Methods. From February 2020 to …
three‐port thoracoscopic lobectomy for lung cancer. Methods. From February 2020 to …
The accuracy and usefulness of the National Comprehensive Cancer Network Evidence Blocks affordability rating
AP Mitchell, P Dey, JA Ohn, SM Tabatabai… - …, 2020 - Springer
Abstract Background The National Comprehensive Cancer Network (NCCN) Guidelines'
Evidence Blocks has the broadest scope of the several oncology value assessment …
Evidence Blocks has the broadest scope of the several oncology value assessment …
[HTML][HTML] Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in hematologY added value framework for hematologic malignancies …
F Cerisoli, F Ali, T Bereczky, N Bolaños, L Bullinger… - Value in Health, 2022 - Elsevier
Abstract Objectives The Innovative Medicines Initiative–funded, multistakeholders project
Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology …
Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology …